CureVac initiates H5N1 avian influenza vaccine study

Curevac has commenced the first phase of a combined Phase I/II clinical trial of a pre-pandemic vaccine candidate targeting the H5N1 avian influenza virus.

Developed in collaboration with GSK, the investigational influenza A (H5N1) pre-pandemic vaccine candidate aims to prepare for potential future pandemic threats.